| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1971024 | Clinical Biochemistry | 2009 | 4 Pages |
Abstract
ObjectiveCan biochip arrays identify which individuals with metastatic disease will respond to an anti-metastatic agent?Design and methodsCytokine and cell adhesion arrays (Randox Ltd) were measured over 1 month in 9 research participants receiving CTCE-9908 in a Phase I/II study.ResultsResearch participants with stable disease (n = 2) had significantly higher soluble VCAM-1 as compared to those that progressed.DiscussionVCAM-1 measurement early during CTCE-9908 treatment might be used as a surrogate for response.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Peter A. Kavsak, Matthew Henderson, Patricia Moretto, Hal Hirte, Ken Evans, Donald Wong, Walter Korz, Sebastien J. Hotte,